Show simple item record

dc.contributor.authorGoel, Gaurav
dc.contributor.authorSun, Weijing
dc.date.accessioned2015-09-01T16:42:41Z
dc.date.available2015-09-01T16:42:41Z
dc.date.issued2015-07-28
dc.identifier.citationJournal of Hematology & Oncology. 2015 Jul 28;8(1):92
dc.identifier.urihttp://dx.doi.org/10.1186/s13045-015-0183-8
dc.identifier.urihttp://hdl.handle.net/10724/31645
dc.description.abstractAbstract The recent FDA approval of ramucirumab (RAISE trial) has added a third agent to our existing armamentarium of angiogenesis inhibitors (bevacizumab and ziv-aflibercept) for the second-line treatment of metastatic colorectal cancer, which may have some impacts in the current clinic practice.
dc.titleRamucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
dc.typeJournal Article
dc.date.updated2015-07-29T18:05:52Z
dc.language.rfc3066en
dc.rights.holderGoel and Sun.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record